Patents by Inventor Jixian TANG

Jixian TANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220251173
    Abstract: Antibodies (especially humanized antibodies) against the hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding same, a method for preparing same, and a pharmaceutical composition containing same. The anti-HBsAg antibodies have a higher binding affinity to HBsAg at a neutral pH than at an acidic pH, thereby significantly enhancing virus clearance efficiency and prolonging virus inhibition time. The antibodies and pharmaceutical composition may be used to prevent and/or treat HBV infections or diseases related to HBV infection (such as hepatitis B) for use in neutralizing the virulence of HBV in the body of a subject (such as a human) to reduce a serum level of HBV DNA and/or HBsAg in the body of the subject, or to activate a humoral immune response of a subject (such as a person infected with chronic HBV or a patient who has chronic hepatitis B) against HBV.
    Type: Application
    Filed: May 22, 2020
    Publication date: August 11, 2022
    Applicants: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.
    Inventors: Wenxin LUO, Yichao JIANG, Chao YU, Xiaoqing CHEN, Jixian TANG, Quan YUAN, Tianying ZHANG, Ningshao XIA
  • Publication number: 20220235117
    Abstract: Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and/or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and/or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 28, 2022
    Applicants: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.
    Inventors: Wenxin LUO, Can WEN, Xinchu XIANG, Jixian TANG, Yangtao WU, Tianying ZHANG, Quan YUAN, Ningshao XIA